HOUSTON, NOVEMBER 19, 2026 ― Patients with multiple myeloma who developed a serious gastrointestinal side effect after treatment with chimeric antigen receptor (CAR) T cell therapy had significantly more CAR T cells persisting in their blood stream, according to new research from The University of Texas MD Anderson Cancer Center . The findings, published in Nature Medicine , may help clinicians better diagnose and treat affected patients earlier.
Immune effector cell-associated enterocolitis (IEC-EC) is a rare but serious gastrointestinal side effect that can occur in patients after CAR T cell therapy. The complication is associated with severe clinical outcomes, including prolonged hospitalization, need for intensive nutritional support and increased mortality.
In the study, patients treated with the CAR T cell therapy ciltacabtagene autoleucel (cilta-cel) who developed IEC-EC had dramatically higher levels of long-term CAR T cell persistence in their blood – more than 100 times higher, on average, than patients who did not develop the condition.
"Our study found that IEC-EC is not just inflammation of the gastrointestinal tract, but it is a distinct CAR T cell therapy-driven immune cell disorder," said the study's corresponding author Mark Hamilton, M.D. , assistant professor of Lymphoma & Myeloma . "By understanding the biology behind this complication, we can improve recognition of the syndrome and develop more effective strategies to monitor and treat patients."
What were the study's key findings?
Researchers analyzed nine cases of IEC-EC occurring among 158 patients treated with cilta-cel. IEC-EC occurred in approximately 5% of patients who received treatment. The study found that these patients had roughly 100-fold higher levels of CAR T cells remaining in their bodies long after treatment compared to patients who did not develop the condition. IEC-EC caused persistent diarrhea and inflammation.
Researchers analyzed tissue samples and discovered that the CAR T cells had accumulated in the digestive tract, where they appeared to drive ongoing inflammation and damage. This suggests that prolonged CAR T cell activity may be a key factor behind this rare but potentially life-threatening complication.
How will these findings improve patient care?
As CAR T cell therapies continue to transform outcomes for patients with multiple myeloma, understanding uncommon but serious toxicities has become increasingly important. Researchers suggest that routine monitoring of CAR T cell persistence could potentially help identify patients who are at higher risk for IEC-EC, providing an opportunity for earlier intervention.
According to the study, an endoscopic evaluation of the duodenum – the upper part of the small intestine – and testing for CAR T cells in a patient's tissue could accelerate diagnosis and treatment for patients who develop gastrointestinal symptoms after treatment. Additional studies are needed to fully understand which patients are most likely to develop the condition and how best to prevent it.